Melasma. Chloasma
Conditions
Interventions
Intervention 1: Intervention group A: Patients use the Kligman-like topical formula on one side of the face every other day for 2 months and microneedling with 10% tranhexamic acid on the other side f
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age 18 to 60 years old Clinical diagnosis of bilateral melasma of the cheek
Exclusion criteria
Exclusion criteria: Patients who have received any treatment for melasma in the past 1 month. Patients who have contraindications to tranexamic acid. (Includes known drug allergy, intracranial hemorrhage, known color vision disorder, history of arterial or venous thromboembolism or active thromboembolic disease, ischemic heart disease, and stroke) Patients with mental instability (which is expected to affect the study process). Patients who do not have informed consent to participate in the study. Patients who do not have the opportunity to visit regularly and cooperate for scoring and follow-up sessions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy. Timepoint: One and two months after the start of treatment and one and four months after the end of treatment. Method of measurement: By modified Melasma Area & Severity Index and Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety. Timepoint: One and two months after the start of treatment and one and four months after the end of treatment. Method of measurement: Ask from the patient for possible adverse effects.;Satisfaction. Timepoint: One and two months after the start of treatment and one and four months after the end of treatment. Method of measurement: Based on patient scoring. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzadeh Goodarzi
Iran University of Medical Sciences
Outcome results
None listed